These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Borrelli O; Salvia G; Mancini V; Santoro L; Tagliente F; Romeo EF; Cucchiara S Am J Gastroenterol; 2005 Mar; 100(3):695-702. PubMed ID: 15743370 [TBL] [Abstract][Full Text] [Related]
46. Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Ferrero V; Ribichini F; Rognoni A; Marino P; Brunelleschi S; Vassanelli C Am J Cardiol; 2007 Apr; 99(8):1082-6. PubMed ID: 17437731 [TBL] [Abstract][Full Text] [Related]
47. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756 [TBL] [Abstract][Full Text] [Related]
48. The treatment of idiopathic sudden sensorineural hearing loss using pulse therapy: a prospective, randomized, double-blind clinical trial. Westerlaken BO; de Kleine E; van der Laan B; Albers F Laryngoscope; 2007 Apr; 117(4):684-90. PubMed ID: 17415139 [TBL] [Abstract][Full Text] [Related]
49. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Griggs RC; Moxley RT; Mendell JR; Fenichel GM; Brooke MH; Pestronk A; Miller JP Arch Neurol; 1991 Apr; 48(4):383-8. PubMed ID: 2012511 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925 [TBL] [Abstract][Full Text] [Related]
51. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336 [TBL] [Abstract][Full Text] [Related]
52. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270 [TBL] [Abstract][Full Text] [Related]
53. Deflazacort treatment of Duchenne muscular dystrophy. Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511 [TBL] [Abstract][Full Text] [Related]
54. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Escolar DM; Hache LP; Clemens PR; Cnaan A; McDonald CM; Viswanathan V; Kornberg AJ; Bertorini TE; Nevo Y; Lotze T; Pestronk A; Ryan MM; Monasterio E; Day JW; Zimmerman A; Arrieta A; Henricson E; Mayhew J; Florence J; Hu F; Connolly AM Neurology; 2011 Aug; 77(5):444-52. PubMed ID: 21753160 [TBL] [Abstract][Full Text] [Related]
55. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Balagopal P; Olney R; Darmaun D; Mougey E; Dokler M; Sieck G; Hammond D Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E530-9. PubMed ID: 16263771 [TBL] [Abstract][Full Text] [Related]
56. Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy. Moxley RT; Pandya S Neurology; 2011 Aug; 77(5):416-7. PubMed ID: 21753162 [No Abstract] [Full Text] [Related]
57. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C; J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228 [TBL] [Abstract][Full Text] [Related]
58. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436 [TBL] [Abstract][Full Text] [Related]
59. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Jefferies JL; Eidem BW; Belmont JW; Craigen WJ; Ware SM; Fernbach SD; Neish SR; Smith EO; Towbin JA Circulation; 2005 Nov; 112(18):2799-804. PubMed ID: 16246949 [TBL] [Abstract][Full Text] [Related]
60. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy]. Sun SC; Peng YS; He JB Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]